Kodani Eitaro, Akao Masaharu
Department of Cardiovascular Medicine, Nippon Medical School Tama-Nagayama Hospital, 1-7-1, Nagayama, Tama-shi, Tokyo 206-8512, Japan.
Department of Cardiology, National Hospital Organization Kyoto Medical Center, 1-1, Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, Japan.
Eur Heart J Suppl. 2020 Dec 22;22(Suppl O):O1-O13. doi: 10.1093/eurheartj/suaa176. eCollection 2020 Dec.
Atrial fibrillation (AF) increases the risk of thromboembolism, and risk assessment for thromboembolism is necessary for the management of AF patients. CHADS2 and CHA2DS2-VASc scores have been adopted in international guidelines for AF management, but the significance of each risk factor included in these risk scores are sometimes controversial, and the performance of these scores is only modest. There are several other risk factors not included in the scores such as renal dysfunction, low body weight, type of AF (paroxysmal or non-paroxysmal) as well as echocardiographic parameters and blood biomarkers, and physicians should assess patients risk in an integrated manner.
心房颤动（AF）会增加血栓栓塞风险，对于房颤患者的管理而言，进行血栓栓塞风险评估很有必要。CHADS2和CHA2DS2-VASc评分已被纳入房颤管理的国际指南，但这些风险评分中所包含的各个风险因素的意义有时存在争议，且这些评分的表现也只是一般。还有一些风险因素未包含在这些评分中，如肾功能不全、低体重、房颤类型（阵发性或非阵发性）以及超声心动图参数和血液生物标志物，医生应综合评估患者的风险。
